Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | HTR6 | P50406 | 2/20 | 0.77 |
| ▸ | MPO | P05164 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | HTR1D | P28221 | 1/20 | 0.77 |
| ▸ | HTR1B | P28222 | 1/20 | 0.77 |
| ▸ | HTR7 | P34969 | 1/20 | 0.77 |
| ▸ | CTSK | P43235 | 1/20 | 0.77 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.77 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | AHR | P35869 | 1/20 | 0.75 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004146 | 0.91 | HTR2A (0.71) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7005718 | 0.91 | HTR2A (0.71) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL8524609 | 0.90 | MEN1 (0.70) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7889427 | 0.89 | HTR2A (0.69) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7001306 | 0.89 | HTR2A (0.69) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7004071 | 0.89 | HTR2A (0.69) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL91128 | 0.87 | HTR2A (0.72) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL219533 | 0.87 | HTR2A (0.67) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL5522209 | 0.87 | HTR2A (0.67) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL4229484 | 0.87 | HTR2A (0.67) | HTR2ACYP3A4HTR2CHTR6MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | claimed |
| CN-108546244-B | Synthetic method of 3, 3' -diindolylethane compound | 南昌航空大学 | 2021-04-23 | — | — | CN | disclosed |
| CN-108546244-B | Synthetic method of 3, 3' -diindolylethane compound | 南昌航空大学 | 2021-04-23 | — | — | CN | disclosed |
| EP-2174979-B1 | Resin composition and resin molded product | SONY CORP (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-7348352-B2 | Diindolylmethane for the treatment of HPV infection | BIORESPONSE L.L.C. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015813-A1 | Treatment of protein folding disorders | HSPA5, TTR, TUFM | HTR2A 536/4885CYP3A4 4221/4885HTR2C 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.